SEC Form 4/A · accession 0001493152-17-004208
OncBioMune Pharmaceuticals, Inc · OBMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Jonathan Frederick Head
Officer — Chief Excecuite Officer · Director · 10% Owner
Period of report
Mar 10, 2017
Accepted (ET)
Apr 20, 2017 · 8:44 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001362703
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF1 | Mar 10, 2017 | J | 2,892,000 | — | A | 2,892,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2,F1,F3 | $0.25 | Mar 10, 2017 | A | 2,000,000 | A | — | Mar 10, 2027 | Common Stock | 2,000,000 | 2,000,000 | D |
Explanation of responses
- F1Securities issued pursuant to the terms and conditions of a Contribution Agreement to the Property of Trust F/2868 entered into among OncBioMune Pharmaceuticals, Inc., Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie dated March 10, 2017 as filed by the Issuer as Exhibit 10.1 to its Current Report on Form 8-K as filed with the SEC on March 13, 2017.
- F2Amended to include stock option award.
- F3One-third of the Stock Options vest on March 10, 2018, March 10, 2019 and March 10, 2020.